Krystal Biotech, Inc. (KRYS)
322.28
-3.03
(-0.93%)
USD |
NASDAQ |
Oct 02, 16:00
322.46
+0.18
(+0.06%)
After-Hours: 20:00
Krystal Biotech Market Cap : 9.538B for Oct. 2, 2026
Market Cap Chart
Historical Market Cap Data
| Date | Value |
|---|---|
| October 02, 2026 | 9.538B |
| October 01, 2026 | 9.628B |
| September 30, 2026 | 9.842B |
| September 29, 2026 | 9.916B |
| September 28, 2026 | 9.976B |
| September 25, 2026 | 10.23B |
| September 24, 2026 | 10.21B |
| September 23, 2026 | 10.11B |
| September 22, 2026 | 10.38B |
| September 21, 2026 | 9.881B |
| September 18, 2026 | 9.964B |
| September 17, 2026 | 10.03B |
| September 16, 2026 | 9.964B |
| September 15, 2026 | 9.964B |
| September 14, 2026 | 10.06B |
| September 11, 2026 | 10.27B |
| September 10, 2026 | 10.23B |
| September 09, 2026 | 10.30B |
| September 08, 2026 | 10.40B |
| September 04, 2026 | 10.60B |
| September 03, 2026 | 10.99B |
| September 02, 2026 | 10.93B |
| September 01, 2026 | 10.77B |
| August 31, 2026 | 10.64B |
| August 28, 2026 | 10.40B |
| Date | Value |
|---|---|
| August 27, 2026 | 10.58B |
| August 26, 2026 | 10.65B |
| August 25, 2026 | 10.54B |
| August 24, 2026 | 10.11B |
| August 21, 2026 | 10.26B |
| August 20, 2026 | 9.974B |
| August 19, 2026 | 10.16B |
| August 18, 2026 | 9.850B |
| August 17, 2026 | 9.936B |
| August 14, 2026 | 9.834B |
| August 13, 2026 | 9.718B |
| August 12, 2026 | 9.851B |
| August 11, 2026 | 9.679B |
| August 10, 2026 | 9.814B |
| August 07, 2026 | 9.662B |
| August 06, 2026 | 9.550B |
| August 05, 2026 | 9.642B |
| August 04, 2026 | 9.612B |
| August 03, 2026 | 9.201B |
| July 31, 2026 | 10.04B |
| July 30, 2026 | 10.80B |
| July 29, 2026 | 10.69B |
| July 28, 2026 | 10.72B |
| July 27, 2026 | 10.36B |
| July 24, 2026 | 9.867B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| TG Therapeutics, Inc. | 8.311B |
| Cytokinetics, Inc. | 9.103B |
| Alnylam Pharmaceuticals, Inc. | 29.38B |
| Exelixis, Inc. | 14.53B |
| Regeneron Pharmaceuticals, Inc. | 76.02B |
Market Cap Related Metrics
| PE Ratio | 40.39 |
| PS Ratio | 22.18 |
| PEG Ratio | 0.648 |
| Price to Book Value | 7.018 |
| Price to Free Cash Flow | 37.90 |
| Price | 322.28 |
| Earnings Yield | 2.48% |
| PEGY Ratio | 0.648 |
| Operating PE Ratio | 49.40 |
| Normalized PE Ratio | 40.39 |